LumiraDx Limited is a diagnostics & research business based in the US. LumiraDx Limited shares (LMDX) are listed on the NASDAQ and all prices are listed in US Dollars. LumiraDx Limited employs 1,513 staff and has a trailing 12-month revenue of around $331.6 million.
Finder Award
SoFi Invest
Finder Award
eToro
Robinhood
| Latest market close | $0.98 |
|---|---|
| 52-week range | $0.77 - $9.43 |
| 50-day moving average | $1.05 |
| 200-day moving average | $2.04 |
| Wall St. target price | $3.49 |
| PE ratio | 8.8 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.10 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.9799 from 2023-02-01
| 1 week (2023-01-26) | 11.35% |
|---|---|
| 1 month (2023-01-03) | 10.10% |
| 3 months (2022-11-03) | -5.78% |
| 6 months (2022-08-03) | -40.61% |
| 1 year (2022-02-03) | -88.98% |
|---|---|
| 2 years (2021-01-30) | N/A |
| 3 years (2020-01-30) | N/A |
| 5 years (2018-01-30) | N/A |
Valuing LumiraDx Limited stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of LumiraDx Limited's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
LumiraDx Limited's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 9x. In other words, LumiraDx Limited shares trade at around 9x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
However, LumiraDx Limited's P/E ratio is best considered in relation to those of others within the diagnostics & research industry or those of similar companies.
| Revenue TTM | $331.6 million |
|---|---|
| Gross profit TTM | $151.5 million |
| Return on assets TTM | -18.22% |
| Return on equity TTM | -378.14% |
| Profit margin | -115.87% |
| Book value | $0.06 |
| Market capitalisation | $279.6 million |
TTM: trailing 12 months
We're not expecting LumiraDx Limited to pay a dividend over the next 12 months.
LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has approximately 30 tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions from the lab to point of need. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company was founded in 2014 and is headquartered in London, the United Kingdom. .
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.